Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of ensartinib in advanced ALK-positive NSCLC after prior ALK inhibitor failure
ChiCTR2200057754Phase 4Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ensartinib in non-small cell lung cancer (NSCLC) and ALK-positive non-small cell lung cancer, sponsored by Beijing Tiantan Hospital. Primary endpoint: Objective Response Rate. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on ChiCTR2200057754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057754.